ConcertAI’s Post

Are you struggling with duplicate and professional research subjects? Look no further than Verified Clinical Trials ™ (VCT)! VCT is a cross-sponsor database that covers phase I-IV across multiple therapeutic indications globally. With VCT, you can save time and money while ensuring your clinical trial meets its endpoints. Contact VCT at connect@verifiedclinicaltrials.com to learn more! #duplicatesubjects #verifiedclinicaltrials #placebo

Are you struggling with duplicate and professional research subjects? Look no further than Verified Clinical Trials ™ (VCT)! VCT is a cross-sponsor database that covers phase I-IV across multiple therapeutic indications globally. With VCT, you can save time and money while ensuring your clinical trial meets its endpoints. Contact VCT at connect@verifiedclinicaltrials.com to learn more! #duplicatesubjects #verifiedclinicaltrials #placebo

Are you struggling with duplicate and professional research subjects? Look no further than Verified Clinical Trials ™ (VCT)! VCT is a cross-sponsor database that covers phase I-IV across multiple therapeutic indications globally. With VCT, you can save time and money while ensuring your clinical trial meets its endpoints. Contact VCT at connect@verifiedclinicaltrials.com to learn more! #duplicatesubjects #verifiedclinicaltrials #placebo

Are you struggling with duplicate and professional research subjects? Look no further than Verified Clinical Trials ™ (VCT)! VCT is a cross-sponsor database that covers phase I-IV across multiple therapeutic indications globally. With VCT, you can save time and money while ensuring your clinical trial meets its endpoints. Contact VCT at connect@verifiedclinicaltrials.com to learn more! #duplicatesubjects #verifiedclinicaltrials #placebo

Are you struggling with duplicate and professional research subjects? Look no further than Verified Clinical Trials ™ (VCT)! VCT is a cross-sponsor database covering phase I-IV across multiple therapeutic indications globally. With VCT, you can save time and money while ensuring your clinical trial meets its endpoints. Contact VCT at connect@verifiedclinicaltrials.com to learn more! #duplicatesubjects #verifiedclinicaltrials #placeboresponse

Check out the webcast next Wednesday (7/17) to learn about Adverum’s advances in the treatment of nAMD!

Today, we announced a bempikibart program update, including topline results from our SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart (ADX-914), which demonstrated encouraging clinical activity in patients with #alopeciaareata (AA). Read the full press release: https://bit.ly/3ZL9ZhH 

Practice makes perfect! Launching a new clinical trial requires thorough team preparation. One example is the radioactive water (O15-H2O) trial, sponsored by MedTrace Pharma A/S. This trial explores the efficacy of using O15 to help detect clogged blood vessels and improve detection of coronary artery disease. O15 has a very short half-life of only 2-minutes which requires precise team coordination. Using the MedTrace P3 machine, we quickly convert O15 gas into O15 water. https://hubs.la/Q02vkkHx0 To learn more about this trial, visit: https://hubs.la/Q02vkksv0

#CGIC24 Day 2 centered on the importance of every valuable data point in rare and orphan diseases. The session on Refining the Use of Data to Manage Uncertainty explored how to effectively harness data to navigate uncertainties in the field. In an era of information overload, the significance of data-driven decision-making cannot be overstated. By eliminating biases and subjective judgments, this approach ensures decisions are grounded in objective data and evidence, leading to more informed and impactful outcomes. Kristin Hatcher "Every hospital stay he had [speaking about her father], my mom took notes. She had twice as many as the EHR, but she didn't have anywhere to put them. I am a part of nine different support groups online and we post our EHR data, we post our fit bit information and it's out there. We just don't know what to do with it. There are many things to me, as an ALPHA-1 patient that are included that aren't being captured [in the EHR] that effect my everyday life that no one has even touched upon." Kristin Van Goor (Takeda): "This is a really exciting point because we have been working on this for two years now and it's starting to be tangible, and it's starting to be real. We're now at the point where we know the data sets are out there, we are actively talking about bringing them in house to C-Path and interrogating them in a way that hasn't been done before. It's coming at a really critical time in AATD drug development." Gina Smith Sorin Fedeles, PhD, MBA Aliza Thompson Kristin Hatcher Global Liver Institute Frank Czerwiec (Sparrow Pharmaceuticals, Inc.) Kristin Van Goor Takeda Kerry Jo Lee (FDA) #CPath #CGIC24 #DrugDevelopment #neutral #datasharing #globalhealth #collaboration #regulatoryscience #DHTs #DDTs

🎥 MPE interviewed Dr. Laurent Garderet, co-author of the IFM2017-03 phase 3 trial abstract presented today at ASH 2024. The trial analyses a dexamethasone-sparing regimen with daratumumab and lenalidomide for frail patients with newly diagnosed myeloma. Dr. Garderet explains key findings, including significant improvements in progression-free survival (PFS) and quality of life benefits for these patients. #ASH2024 #Myeloma #MPEatASH2024 https://lnkd.in/dy885Wg5